Attending this event?
Back To Schedule
Wednesday, June 22 • 4:15pm - 5:15pm
#378: US Health Care System Adoption of a Class of New Technologies for the Treatment of Alzheimer’s Disease: Access Challenges and Opportunities

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Forum
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-22-646-L04-P ; CME 1.00; RN 1.00

A new class of monoclonal antibodies have reached a milestone in elucidating more on the pathology of AD and this pathology can be affected by treatment to alter progression. Current US HC delivery system for mild-cognitive impairment (MCI) AD patients do not have an efficient, well-established care processes to adopt the new MAB technology which requires care steps not presently being done or coordinated across care settings other than centers of excellence (e.g., Diagnostics such as Positron Electron Tomography, Cerebral Spinal Fluid tap, MRI). The MAB class has focused primarily on studying earlier stages in AD disease progression given the predominant belief that treating progressive neurologic diseases earlier with an efficacious treatment will result in better health outcomes than initiating treatment in later stages of AD. There may be a barrier to adoption if the current health care system will require screening of patients for mild MCI. How can a new technology which can affect the disease process overcome the challenge that anyone who is experiencing mild MCI may be early stage of disease versus dismissed as “getting old”? A panel composed of the relevant stakeholders will have a semi-structured discussion on the access challenges and opportunities of adoption of the new and upcoming class of therapeutic agents for the treatment of the underlying pathology in Alzheimer’s Disease.

Learning Objectives

Identify the access challenges and barriers for adoption of a class of monoclonal antibodies (MAB) which treat underlying pathology in Alzheimer’s Disease.


Phil Sarocco, MPharm, MS


Yash J. Jalundhwala, PhD, MS

Brian S. Mittman, PhD, MA

Tony Grillo, PharmD

Darren Gitelman, MD

avatar for Darren Gitelman

Darren Gitelman

Senior Medical Director, Advocate Memory Center, Advocate Lutheran General Hospital, United States
Dr. Gitelman is a behavioral neurologist who serves at the Director of Cognitive Disorders for the Advocate Medical Group, the Advocate Aurora Health Neuroscience Service Line Medical Research Director, and the Senior Medical Director of the Advocate Memory Center. He is a Clinical... Read More →
avatar for Tony Grillo

Tony Grillo

Managing Director, Pharma Strategy & Contracting, Evernorth, United States
Tony Grillo is a Pharmacist with over 20 years’ experience in pharmacy and pharmacy benefit management. During that time, he has had a wide variety of roles and experience working in pharmacy practice, specialty pharmacy, clinical operations, drug trend and utilization management... Read More →
avatar for Yash Jalundhwala

Yash Jalundhwala

Director, Neuroscience, Global Market Access and Pricing, AbbVie, United States
Dr. Yash J Jalundhwala is currently the global lead for Market Access and Pricing at AbbVie supporting a portfolio of innovative treatments for Alzheimer's Disease. He has also previously served as the Health Economics and Outcomes Research lead for Parkinson's and Alzheimer's Disease... Read More →
avatar for Brian Mittman

Brian Mittman

Research Scientist, Div of Health Services Research and Implementation Science, Kaiser Permanente Southern California, United States
Brian Mittman is a Senior Scientist at Kaiser Permanente Southern California with additional affiliations at USC and UCLA. His research interests include implementation and improvement science, embedded research within learning healthcare systems, and innovative methods for the study... Read More →
avatar for Phil Sarocco

Phil Sarocco

Head of Health Economics & Outcomes Research and field Medical Accounts, Biogen, United States

Wednesday June 22, 2022 4:15pm - 5:15pm CDT
Room 179 McCormick Place 2301 South Indiana Avenue Gate 40 Chicago, IL 60616
  12: Value-Access, Forum